The global brain tumor drugs market size was estimated to be USD 1.99 billion in 2023 and is expected to reach at USD 6.14 billion by 2034 with a CAGR of 10.46% during the forecast period 2024-2034. Surge in prevalence of brain cancer, rising prevalence of smoking, growing geriatric population, increasing research & development activities, rising launch of new drugs, growing focus on the development of novel drugs, increasing demand for early diagnosis & treatment of brain cancer, and surge in approvals by regulatory bodies are some of the key factors boosting the market growth.
Surge in approvals by regulatory bodies is predicted to boost the market growth during the forecast period. Companies are focusing on development & launch of advanced test products for brain tumor diagnosis which anticipates the approvals from regulatory bodies. For instance, in January 2023, The European Medicines Agency (EMA) has granted orphan drug status to Vorasidenib, a medication created by Les Laboratories Servier, with the purpose of treating low-grade gliomas.
By therapy, immunotherapy was the highest revenue-grossing segment in the global brain tumor drugs market in 2023 owing to the rising focus on the development of novel immunotherapies, growing approvals of immunotherapies for various brain cancers, increasing launch of new immunotherapies for brain tumors, surge in research & development activities, and rising approvals by regulatory bodies. For instance, in December 2022, In8bio Inc., a biopharmaceutical firm, has obtained Investigational New Drug (IND) clearance from the U.S. FDA to initiate a phase 2 clinical trial for its exclusive drug-resistant immunotherapy aimed at individuals newly diagnosed with glioblastoma. Additionally, chemotherapy is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for adjuvant therapy, and increasing adoption of chemotherapy as a first line of treatment.
By indication, glioblastoma was the highest revenue-grossing segment in the global brain tumor drugs market in 2023 owing to the surge in prevalence of malignant brain tumor, surge in launch of novel drugs by regulatory bodies, and increasing number of clinical trials. For instance, in March 2022, The Ivy Brain Tumor Centre has commenced a phase 0/1b clinical trial to investigate the effectiveness of AZD1390, a drug developed by AstraZeneca, in individuals afflicted with recurrent grade IV gliomas. Additionally, meningioma is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of meningioma, growing research & development activities, and surge in development of new drugs.
By distribution channel, hospital pharmacy was the highest revenue-grossing segment in the global brain tumor drugs market in 2023 owing to the surge in administration of brain tumor drugs in hospitals, and rising collaborations within market players. For instance, in September 2022, Good Therapeutics, a privately-owned firm, has disclosed its agreement to be acquired by Roche through a definitive merger deal. This acquisition will provide Roche with access to Good Therapeutics' groundbreaking PD-1-regulated IL-2 program, which is conditionally active. Additionally, Roche will secure exclusive rights to the platform technology used for developing PD-1-regulated IL-2 receptor agonist therapies. Additionally, retail pharmacy is predicted to grow at fastest CAGR during the forecast period owing to the increasing preference of retail pharmacies by consumers and growing launch of novel drugs.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing awareness regarding advanced technologies, increasing prevalence of brain tumors, surge in product launches & drug approvals, rising research & development activities for the treatment of brain tumors, growing number of clinical trials for brain tumor therapeutics, and increasing approvals by regulatory bodies. For instance, in April 2022, Amneal Pharmaceuticals LLC has obtained approval from the U.S. FDA for ALYMSYS (bevacizumab-maly), a biosimilar version of Avastin. This approval allows it to be used in the treatment of various cancer types, including recurrent glioblastoma in adults. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising awareness regarding the cancer among population, increasing launch of innovative drugs, and growing regulatory approvals for novel drugs. For instance, in June 2022, FDA clearance has been granted to Novartis AG for the use of Tafinlar + Mekinist in the treatment of both pediatric and adult patients with solid tumors carrying the BRAF V600E mutation. This mutation is responsible for driving tumor growth in over 20 tumor types, including those found in the brain, thyroid, and various others.
Surge in approvals by regulatory bodies is predicted to boost the market growth during the forecast period. Companies are focusing on development & launch of advanced test products for brain tumor diagnosis which anticipates the approvals from regulatory bodies. For instance, in January 2023, The European Medicines Agency (EMA) has granted orphan drug status to Vorasidenib, a medication created by Les Laboratories Servier, with the purpose of treating low-grade gliomas.
By therapy, immunotherapy was the highest revenue-grossing segment in the global brain tumor drugs market in 2023 owing to the rising focus on the development of novel immunotherapies, growing approvals of immunotherapies for various brain cancers, increasing launch of new immunotherapies for brain tumors, surge in research & development activities, and rising approvals by regulatory bodies. For instance, in December 2022, In8bio Inc., a biopharmaceutical firm, has obtained Investigational New Drug (IND) clearance from the U.S. FDA to initiate a phase 2 clinical trial for its exclusive drug-resistant immunotherapy aimed at individuals newly diagnosed with glioblastoma. Additionally, chemotherapy is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for adjuvant therapy, and increasing adoption of chemotherapy as a first line of treatment.
By indication, glioblastoma was the highest revenue-grossing segment in the global brain tumor drugs market in 2023 owing to the surge in prevalence of malignant brain tumor, surge in launch of novel drugs by regulatory bodies, and increasing number of clinical trials. For instance, in March 2022, The Ivy Brain Tumor Centre has commenced a phase 0/1b clinical trial to investigate the effectiveness of AZD1390, a drug developed by AstraZeneca, in individuals afflicted with recurrent grade IV gliomas. Additionally, meningioma is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of meningioma, growing research & development activities, and surge in development of new drugs.
By distribution channel, hospital pharmacy was the highest revenue-grossing segment in the global brain tumor drugs market in 2023 owing to the surge in administration of brain tumor drugs in hospitals, and rising collaborations within market players. For instance, in September 2022, Good Therapeutics, a privately-owned firm, has disclosed its agreement to be acquired by Roche through a definitive merger deal. This acquisition will provide Roche with access to Good Therapeutics' groundbreaking PD-1-regulated IL-2 program, which is conditionally active. Additionally, Roche will secure exclusive rights to the platform technology used for developing PD-1-regulated IL-2 receptor agonist therapies. Additionally, retail pharmacy is predicted to grow at fastest CAGR during the forecast period owing to the increasing preference of retail pharmacies by consumers and growing launch of novel drugs.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing awareness regarding advanced technologies, increasing prevalence of brain tumors, surge in product launches & drug approvals, rising research & development activities for the treatment of brain tumors, growing number of clinical trials for brain tumor therapeutics, and increasing approvals by regulatory bodies. For instance, in April 2022, Amneal Pharmaceuticals LLC has obtained approval from the U.S. FDA for ALYMSYS (bevacizumab-maly), a biosimilar version of Avastin. This approval allows it to be used in the treatment of various cancer types, including recurrent glioblastoma in adults. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising awareness regarding the cancer among population, increasing launch of innovative drugs, and growing regulatory approvals for novel drugs. For instance, in June 2022, FDA clearance has been granted to Novartis AG for the use of Tafinlar + Mekinist in the treatment of both pediatric and adult patients with solid tumors carrying the BRAF V600E mutation. This mutation is responsible for driving tumor growth in over 20 tumor types, including those found in the brain, thyroid, and various others.
Segmentation: Brain Tumor Drugs Market Report 2022 - 2033
Brain Tumor Drugs Market Analysis & Forecast by Therapy 2023 - 2034 (Revenue USD Bn)
- Gene Therapy
- Chemotherapy
- Immunotherapy
- Other
Brain Tumor Drugs Market Analysis & Forecast by Indication 2023 - 2034 (Revenue USD Bn)
- Pituitary Tumors
- Glioblastoma
- Meningioma
- Other
Brain Tumor Drugs Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Retail Pharmacy
- Hospital Pharmacy
- Others
Brain Tumor Drugs Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Brain Tumor Drugs Market: Therapy Estimates & Trend Analysis
8. Brain Tumor Drugs Market: Indication Estimates & Trend Analysis
9. Brain Tumor Drugs Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Brain Tumor Drugs Market
12. Europe Global Brain Tumor Drugs Market
13. Asia Pacific Global Brain Tumor Drugs Market
14. Latin America Global Brain Tumor Drugs Market
15. MEA Global Brain Tumor Drugs Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Novartis AG
- Amgen Inc.
- Johnson & Johnson
- Bayer AG
- AstraZeneca PLC
- Eisai Inc.
- Merck & Co. Inc.
- Pfizer Inc.
- GlaxoSmithKline PLC
- Bristol-Myers Squibb Co.
- F. Hoffmann-La Roche Ltd
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 1.99 Billion |
| Forecasted Market Value ( USD | $ 6.14 Billion |
| Compound Annual Growth Rate | 10.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
